By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Norwegian molecular diagnostic firm DiaGenic, which has developed quantitative real-time PCR-based blood tests for Alzheimer's disease and breast cancer, said today that it has raised NOK70 million ($12.1 million) in a private placement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.